Claims for Patent: 7,198,950

Summary for Patent: 7,198,950

Title:	Methods and compositions relating to restricted expression lentiviral vectors and their applications
Abstract:	The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise promoters active to promote expression specific to cell types or tissues. Further, promoters are providing that are amenable to control by activators, enhancers, or repressors. These vectors are in a self-inactivating configuration for biosaftey. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element, without any decrease in the specificity or control exerted by the promoters. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
Inventor(s):	Trono; Didier (Collonge, CH), Wiznerowicz; Maciej (Geneva, CH)
Assignee:	Institut Clayton de la Recherche (Geneva, CH)
Application Number:	10/261,078
Patent Claims:	1. An in vitro hematopoietic progenitor host cell transduced with a lentivirus comprising a transgene positioned under the control of a promoter that is active to support expression of the transgene in blood cell derivatives of said progenitor, and capable of promoting expression of the transgene in the hematopoietic progenitor cell at a signal-to-noise ratio of between about 10 and about 200. 2. The host cell of claim 1, wherein the promoter promotes expression in cell types selected from the group of mature blood cells, neutrophils, monocytes, and granulocytes. 3. The host cell of claim 1, wherein the lentivirus comprises a central polypurine tract (cPPT) positioned upstream of the trans gene. 4. The host cell of claim 1, wherein the lentivirus is further defined as a self-inactivating lentivirus (SIN). 5. The host cell of claim 1, wherein the promoter is a gp91-phox promoter, a gp47-phox promoter, a CD11b promoter, a beta-globin promoter, an MHC classII promoter, a clotting Factor IX promoter, an insulin promoter, a PDX1 promoter, a CD4 promoter, or a CD2 promoter. 6. The host cell of claim 1, wherein the lentivirus comprises at least one enhancer sequence. 7. The host cell of claim 1, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200. 8. The host cell of claim 1, wherein the promoter is capable of promoting expression of the transgene in response to a transcriptional activator. 9. The host cell of claim 1, wherein the transgene is gp91-phox, gp47-phox, erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb.beta., a multidrug resistance gene, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibody (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE, a marker gene, luciferase, or GFP. 10. The host cell of claim 1, wherein the lentivirus comprises a posttranscriptional regulatory sequence positioned to promote the expression of the transgene. 11. The transduced host cell of claim 1, wherein the human hematopoietic progenitor cell is a CD34.sup.+ cell. 12. The method of claim 1, wherein the transgene is gp144-phox, gp47-phox, erythropoietin, an interleukin, a colony-stimulating factor, integrin .alpha.IIb.beta., a multidrug resistance gene, an antiviral gene, a gene coding for blood coagulation factor VIII, a gene coding for blood coagulation factor IX, a T cell antigen receptor, a B cell antigen receptor, a single chain antibody (ScFv), TNF, gamma interferon, CTLA4, B7, Melana, MAGE, a marker gene, luciferase, or GFP. 13. The method of claim 1, wherein the lentivirus comprises a posttranscriptional regulatory sequence positioned to promote the expression of the transgene. 14. The host cell of claim 2, wherein the promoter promotes expression in mature blood cells. 15. The host cell of claim 2, wherein the promoter promotes expression in neutrophils. 16. The host cell of claim 2, wherein the promoter promotes expression in monocytes or granulocytes. 17. The host cell of claim 16, wherein the promoter restricts transcription to monocytes and granulocytes. 18. The host cell of claim 3, wherein the central polypurine tract (cPPT) comprises the nucleotide sequence of SEQ ID NO: 1. 19. The host cell of claim 3, wherein the lentivirus comprises multiple unique cloning sites positioned adjacent to the central polypurine tract (cPPT). 20. The host cell of claim 19, wherein the multiple unique cloning sites are positioned upstream of the central polypurine tract (cPPT). 21. The host cell of claim 19, wherein the multiple unique cloning sites are positioned downstream of the central polypurine tract (cPPT). 22. The host cell of claim 19, wherein multiple unique cloning sites are positioned both upstream and downstream of the central polypurine tract (cPPT). 23. The host cell of claim 4, wherein the LTR region of said lentivirus has reduced transcriptional activity by virtue of deletions in the U3 region of a 3' LTR. 24. The host cell of claim 23, wherein the deletions are of nucleotides at positions -418 through -18 relative to the U3-R region boundary. 25. The host cell of claim 5, wherein the promoter is a gp91-phox promoter. 26. The host cell of claim 5, wherein the promoter is a gp47-phox promoter. 27. The host cell of claim 5, wherein the promoter is a CD11b promoter. 28. The host cell of claim 6, wherein the at least one enhancer sequence is selected from the group of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7. 29. The host cell of claim 6, wherein the lentivirus comprises a central polypurine tract (cPPT). 30. The host cell of claim 29, wherein the at least one enhancer sequence is positioned adjacent to the cPPT. 31. The host cell of claim 29, wherein the at least one enhancer sequence is positioned upstream of the cPPT. 32. The host cell of claim 29, wherein the at least one enhancer sequence is positioned downstream of the cPPT. 33. The host cell of claim 29, wherein enhancer sequences are positioned both upstream and downstream of the cPPT. 34. The host cell of claim 33, wherein the enhancer sequences are selected from the group of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. 35. The host cell of claim 7, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200. 36. The host cell of claim 8, wherein the transcriptional activator is INF-gamma. 37. The host cell of claim 9, wherein the transgene is gp91-phox. 38. The host cell of claim 9, wherein the transgene is gp47-phox. 39. The host cell of claim 9, wherein the transgene comprises a gene coding for a marker gene. 40. The host cell of claim 9, wherein the transgene comprises a gene coding for a GFP. 41. The host cell of claim 10, wherein the posttranscriptional regulatory sequence is an intron. 42. The host cell of claim 10, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element. 43. The host cell of claim 41, wherein the intron is positioned in an orientation opposite that of the lentivirus genomic transcript. 44. The host cell of claim 42, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). 45. The host cell of claim 44, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE). 46. A method for transducing a human hematopoietic stem cell comprising contacting a population of human cells that include hematopoietic stem cells with a lentivirus comprising a transgene positioned under the control of a promoter that is active to support expression of the transgene in the hematopoietic stem cell at a signal-to-noise ratio of between about 10 and about 200, under conditions to effect the transduction of a human hematopoietic stem cell in said population by said vector. 47. The method of claim 46, wherein the human hematopoietic stem cell population comprises CD34.sup.+ cells. 48. The method of claim 46, wherein the cell population is treated to stimulate cell proliferation. 49. The method of claim 46, wherein the stem cell in transduced in vivo. 50. The method of claim 46, wherein the stem cell is transduced in vitro. 51. The method of claim 46, wherein the promoter promotes expression in cell types selected from the group of mature blood cells, neutrophils, monocytes, and granulocytes. 52. The method of claim 46, wherein the lentivirus comprises a central polypurine tract (cPPT) positioned upstream of the transgene. 53. The method of claim 46, wherein the lentivirus is further defined as a self-inactivating lentivirus (SIN). 54. The method of claim 46, wherein the promoter is a gp144-phox promoter, a gp47-phox promoter, a CD11b promoter, a beta-globin promoter, an MHC classII promoter, a clotting Factor IX promoter, an insulin promoter, a PDX1 promoter, a CD4 promoter, or a CD2 promoter. 55. The method of claim 46, wherein the lentivirus comprises at least one enhancer sequence. 56. The method of claim 46, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 40 and about 200. 57. The method of claim 46, wherein the promoter is capable of promoting expression of the transgene in response to a transcriptional activator. 58. A method for expressing a transgene in a restricted set of cell types comprising transducing a human hematopoietic stem cell in accordance with claim 46 and providing for the maturation of the desired cell types. 59. The method of claim 50, wherein the transduced stem cell is infused into a human subject. 60. The method of claim 58, further comprising the step of stimulating expression of the transgene by contacting the promoter with an activator of transcription. 61. The method of claim 51, wherein the promoter promotes expression in mature blood cells. 62. The method of claim 51, wherein the promoter promotes expression in neutrophils. 63. The method of claim 51, wherein the promoter promotes expression in monocytes or granulocytes. 64. The method of claim 63, wherein the promoter restricts transcription to monocytes and granulocytes. 65. The method of claim 52, wherein the central polypurine tract (cPPT) comprises the nucleotide sequence of SEQ ID NO: 1. 66. The method of claim 52, wherein the lentivirus comprises multiple unique cloning sites positioned adjacent to the central polypurine tract (cPPT). 67. The method of claim 66, wherein the multiple unique cloning sites are positioned upstream of the central polypurine tract (cPPT). 68. The method of claim 66, wherein the multiple unique cloning sites are positioned downstream of the central polypurine tract (cPPT). 69. The method of claim 66, wherein multiple unique cloning sites are positioned both upstream and downstream of the central polypurine tract (cPPT). 70. The method of claim 53, wherein the LTR region of said lentivirus has reduced transcriptional activity by virtue of deletions in the U3 region of a 3' LTR. 71. The method of claim 70, wherein the deletions are of nucleotides at positions -418 through -18 relative to the U3-R region boundary. 72. The method of claim 54, wherein the promoter is a gp144-phox promoter. 73. The method of claim 54, wherein the promoter is a gp47-phox promoter. 74. The method of claim 54, wherein the promoter is a CD 11b promoter. 75. The method of claim 55, wherein the at least one enhancer sequence is selected from the group of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. 76. The method of claim 55, wherein the lentivirus comprises a central polypurine tract (cPPT). 77. The method of claim 76, wherein the at least one enhancer sequence is positioned adjacent to the cPPT. 78. The method of claim 76, wherein the at least one enhancer sequence is positioned upstream of the cPPT. 79. The method of claim 76, wherein the at least one enhancer sequence is positioned downstream of the cPPT. 80. The method of claim 76, wherein enhancer sequences are positioned both upstream and downstream of the cPPT. 81. The method of claim 80, wherein the enhancer sequences are selected from the group of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. 82. The method of claim 56, wherein the promoter is capable of promoting expression of the transgene at a signal-to-noise ratio of between about 150 and about 200. 83. The method of claim 57, wherein the transcriptional activator is INF-gamma. 84. The method of claim 12, wherein the transgene is gp144-phox. 85. The method of claim 12, wherein the transgene is gp47-phox. 86. The method of claim 12, wherein the transgene comprises a gene coding for a marker gene. 87. The method of claim 12, wherein the transgene comprises a gene coding for a GFP. 88. The method of claim 13, wherein the posttranscriptional regulatory sequence is an intron. 89. The method of claim 13, wherein the posttranscriptional regulatory sequence is a posttranscriptional regulatory element. 90. The method of claim 88, wherein the intron is positioned in an orientation opposite that of the lentivirus genomic transcript. 91. The method of claim 89, wherein the posttranscriptional regulatory element is woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). 92. The method of claim 91, wherein the posttranscriptional regulatory element is hepatitis B virus posttranscriptional regulatory element (HPRE).

Details for Patent 7,198,950

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-10-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-10-02
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-10-02